Implications of multigene testing for hereditary breast cancer in primary care

被引:2
|
作者
Meghna S Trivedi [1 ]
Katherine D Crew [1 ,2 ,3 ]
机构
[1] Department of Medicine, College of Physicians and Surgeons, Columbia University
[2] Department of Epidemiology, Mailman School of Public Health, Columbia University
[3] Herbert Irving Comprehensive Cancer Center, Columbia University
关键词
Genetic testing; BRCA1; BRCA2; Hereditary breast cancer; Multigene testing;
D O I
暂无
中图分类号
R737.9 [乳腺肿瘤];
学科分类号
100214 ;
摘要
Approximately 1 in 8 women will develop breast cancer during their lifetime and the risk factors include age, family history, and reproductive factors. In women with a family history of breast cancer, there is a proportion in which a gene mutation can be the cause of the predisposition for breast cancer. A careful assessment of family and clinical history should be performed in these women in order to determine if a genetic counseling referral is indicated. In cases of hereditary breast cancer, genetic testing with a multigene panel can identify specific genetic mutations in over 100 genes. The most common genes mutated in hereditary breast cancer are the high-penetrance BRCA1 and BRCA2 genes. In addition, other mutations in high-penetrance genes in familial cancer syndromes and mutations in DNA repair genes can cause hereditary breast cancer. Mutations in low-penetrance genes and variants of uncertain significance may play a role in breast cancer development, but the magnitude and scope of risk in these cases remain unclear, thus the clinical utility of testing for these mutations is uncertain. In women with high-penetrance genetic mutations or lifetime risk of breast cancer > 20%, risk-reducing interventions, such as intensive screening, surgery, and chemoprevention, can decrease the incidence and mortality of breast cancer.
引用
收藏
页码:50 / 57
页数:8
相关论文
共 50 条
  • [1] Clinical evaluation of multigene testing for hereditary breast and ovarian cancer
    Ellisen, Leif
    Kurian, Allison
    Lincoln, Stephen
    Desmond, Andrea
    Mills, Meredith
    Shannon, Kristen
    Gabree, Michelle
    Anderson, Michael
    Kobayashi, Yuya
    Monzon, Federico
    Ford, James
    [J]. CANCER RESEARCH, 2015, 75
  • [2] Technical evaluation of multigene testing for hereditary breast and ovarian cancer
    Lincoln, Stephen
    Kurian, Allison
    Desmond, Andrea
    Nilsen, Geoffrey
    Jacobs, Kevin
    Yang, Shan
    Hart, Reece
    Monzon, Federico
    Ellisen, Leif
    Ford, James
    [J]. CANCER RESEARCH, 2015, 75
  • [3] BRACAnalysis and multigene panel testing needs hereditary cancer care
    Kogawa, Takahiro
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 52 - 52
  • [4] Multigene panel testing for breast cancer patients at high risk for hereditary cancer
    Shin, H-C.
    Yoo, T-K.
    Lee, E.
    Kee, H-B.
    Han, J.
    Kim, Y.
    Moon, H-G.
    Noh, D-Y.
    Han, W.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [5] Multigene panel testing for hereditary breast and ovarian cancer in the province of Ontario
    Jordan Lerner-Ellis
    Chloe Mighton
    Conxi Lazaro
    Nicholas Watkins
    Vanessa Di Gioacchino
    Andrew Wong
    Martin C. Chang
    George S. Charames
    [J]. Journal of Cancer Research and Clinical Oncology, 2021, 147 : 871 - 879
  • [6] Multigene panel testing for hereditary breast and ovarian cancer in the province of Ontario
    Lerner-Ellis, Jordan
    Mighton, Chloe
    Lazaro, Conxi
    Watkins, Nicholas
    Di Gioacchino, Vanessa
    Wong, Andrew
    Chang, Martin C.
    Charames, George S.
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2021, 147 (03) : 871 - 879
  • [7] Economic impact of multigene panel testing for hereditary breast and ovarian cancer
    Byfield, Stacey Dacosta
    Wei, Helen
    DuCharme, Mary
    Lancaster, Johnathan M.
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2021, 10 (03) : 207 - 217
  • [8] The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?
    Eliade, Marie
    Skrzypski, Jeremy
    Baurand, Amandine
    Jacquot, Caroline
    Bertolone, Geoffrey
    Loustalot, Catherine
    Coutant, Charles
    Guy, France
    Fumoleau, Pierre
    Duffourd, Yannis
    Arnould, Laurent
    Delignette, Alexandra
    Padeano, Marie-Martine
    Lepage, Come
    Raichon-Patru, Geraldine
    Boudrant, Axelle
    Bone-Lepinoy, Marie-Christine
    Villing, Anne-Laure
    Charpin, Aurelie
    Peignaux, Karine
    Chevrier, Sandy
    Vegran, Frederique
    Ghiringhelli, Francois
    Boidot, Romain
    Sevenet, Nicolas
    Lizard, Sarab
    Faivre, Laurence
    [J]. ONCOTARGET, 2017, 8 (02) : 1957 - 1971
  • [9] The transfer of multigene panel testing for hereditary breast and ovarian cancer to healthcare: What are the implications for the management of patients and families?
    Lizard, Sarab
    Eliade, Marie
    Skrzypski, Jeremy
    Baurand, Amandine
    Jacquot, Caroline
    Bertolone, Geoffrey
    Loustalot, Catherine
    Coutant, Charles
    Guy, France
    Fumoleau, Pierre
    Duffourd, Yannis
    Arnould, Laurent
    Padeano, Marie-Martine
    Lepage, Come
    Chevrier, Sandy
    Vegran, Frederique
    Sevenet, Nicolas
    Ghiringhelli, Francois
    Boidot, Romain
    Faivre, Laurence
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [10] Multigene panel testing results for hereditary breast cancer in 1325 individuals: Implications for gene selection and considerations for guidelines
    Tsaousis, G. N.
    Tsoulos, N.
    Papadopoulou, E.
    Agiannitopoulos, K.
    Pepe, G.
    Diamantopoulos, N.
    Floros, T. I.
    Iosifidou, R.
    Markopoulos, C.
    Papazisis, K.
    Venizelos, V.
    Xepapadakis, G.
    Banu, E.
    Eniu, D. T.
    Stanculeanu, D. L.
    Ungureanu, A.
    Tansan, S.
    Tekinel, M.
    Yalcin, S.
    Nasioulas, G.
    [J]. ANNALS OF ONCOLOGY, 2019, 30